Navigation Links
AACR's Seventh Annual Landon Awards
Date:2/21/2008

tivating receptors on the surface of the cells. Mendelsohn and his colleagues were the first to propose a new approach to cancer therapy by suggesting that blocking the epidermal growth factor receptor (EGFR) could prevent cancer cell growth and reproduction.

Mendelsohn and his colleagues proved their hypothesis by producing an anti-EGF receptor monoclonal antibody that blocked receptor kinase activation and inhibited cancer cell growth. Mendelsohns findings ignited intense and continued interest in this area of clinical cancer research. Continued research on EGF receptors, carried out by Mendelsohn and numerous collaborators for almost two decades, proved the original demonstration that both inhibition of a growth factor receptor and inhibition of a tyrosine kinase could be useful approaches to creating new categories of anti-cancer agents.

The eventual landmark development of C225, the human chimeric version of the anti-EGF receptor monoclonal antibody, has changed the way some advanced cancers, including advanced head and neck and pancreatic cancers, are treated and it led to the 2004 FDA approval of cetuximab for treatment of advanced colorectal cancer. Today, there are more than 130 active clinical trials using C225 to treat 15 cancer subtypes and two non-cancer diseases.

Dr. John Mendelsohn had a hunch that paid off. When he identified an antibody against the EGF receptor in the early 1980s, he immediately forged ahead on the path to evaluate and develop this antibody as a treatment for tumors that expressed high levels of the receptor and relied on it for growth, said Stanton L. Gerson, M.D., director of the Case Comprehensive Cancer Center and chair of the Dorothy P. Landon-AACR Prize for Translational Cancer Research selection committee.

While the path was arduous, as it often is for pioneers in cancer therapy, Dr. Mendelsohns hypothesis turned out to be spectacular, resulting in a new and effective treat
'/>"/>

Contact: Jennifer Ryan
jennifer.ryan@aacr.org
267-646-0558
American Association for Cancer Research
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Hospital Corporation of America Purchases Seventh CyberKnife(R) System
2. 6th Annual Pinot Noir Summit Inspires Passionate Debate
3. SXC Health Solutions to present at Raymond James 29th Annual Institutional Investors Conference
4. CryoCath Technologies notice of annual meeting
5. Stem Cell Experts and New York Lt. Gov. David Paterson to Participate in 3rd Annual Stem Cell Summit as Keynote Speakers
6. Biannual Antibiotics May Cut Major Cause of Blindness in Africa
7. Mindray to Exhibit at 2008 European Congress of Radiology Annual Meeting
8. Symposium on drug-resistant diseases set for annual AAAS conference
9. Accipiter Life Sciences Announces Nomination of Three Independent Director Candidates for Election to the Penwest Board at the 2008 Annual Meeting
10. Ener1 to Present at February Roth Capital 20th Annual OC Growth Stock Conference
11. Novo Nordisk Files Annual Report with the SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... (PRWEB) May 23, 2013 Teen birth rates ... according to new data released today by the ... the teen birth rate dropped at least 15% in 48 ... , There were also dramatic declines among all racial/ethnic groups ... ,     Birth rates declined 40% or more for Hispanic teens ...
(Date:5/23/2013)... May 23, 2013 To better ... DORMA company, is pleased to announce the release ... for its pacesetting space division products. Provided by ... wallcoverings, the new patterns and colors represent a ... Through meetings with a team of Koroseal experts, ...
(Date:5/23/2013)... can cause rapidly progressing, life threatening meningitis and meningococcal ... have not known how it attaches to the human ... attaches to the airway to colonise", People can be ... while some people progress to invasive disease. To ... how the bacterium colonises the airway. Now that the ...
(Date:5/23/2013)... According to a new market report ... Subscriber Data Management (SDM); Telecom Application Server; Service Creation ... – 2018)", published by MarketsandMarkets, the SDP Market is ... CAGR of 9.15% from 2013 to 2018. , Browse:, ... 84 Figures , 189 Pages ...
(Date:5/23/2013)... May 23, 2013 Verndale, an ... the launch of Current Digital, a business dedicated ... and digital marketing needs. Companies now view content ... business necessity. This can often leave agencies placed ... on preselected software platforms that they may not ...
Breaking Medicine News(10 mins):Health News:Modernfold Debuts New Colors and Patterns for Space Division Products 2Health News:New discovery in fight against deadly meningococcal disease 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies 2Health News:Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies 3
... being punched by electrical pulses could give better delivery ... treatments //including cancer therapy and gene therapy are limited ... cell membranes. Researchers in San Diego, California, have been ... which involves punching tiny holes into cell membranes using ...
... visions of adult stem cells as a less honestly questionable ... ability to sprout different cell types has spawned debate between ... who say it has life-saving potential. The new findings challenge ... directly produce cell types of other tissues and organs.// It ...
... Food and Drug Administration recommended that three popular allergy drugs ... FDA does not have to follow the advice of its ... for making a decision. // ,"Drugs are prescription ... good and harm. Claritin, Allegra and Zyrtec have almost no ...
... Tea derived from the plants Camellia sinensis contains polyphenols ... flavanols, which gives the tea its antioxidant properties. Polyphenols ... oxidative stress. , ... occur naturally in the body and an increased amount ...
... to a new study shows that women with ... 'good' cholesterol when they take oestrogen.// Previous research suggests ... heart disease. Now doctors at Forest University have discovered ... profile responds to HRT. ,An analysis of over ...
... in University of Texas, a novel blood test can detect ... to predict who might get Alzheimer's disease.Researchers at the School ... a similar blood test would work in people, but the ... ruins brain cells and is the cause of Alzheimer's. Some ...
Cached Medicine News:Health News:A question on study of Adult Stem Cell 2Health News:A question on study of Adult Stem Cell 3Health News:Blood test may aid foretell Alzheimer's 2
(Date:5/23/2013)...  Omeros Corporation (NASDAQ: OMER ) ... (IND) to evaluate OMS824 in Huntington,s disease has ... Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), ... linked to a wide range of diseases that ... has shown promising results in animal models directly ...
(Date:5/23/2013)... ATLANTA , May 23, 2013  Inhibikase ... treatments, announced today that it will present new ... at an industry conference sponsored by the PML ... Biogen Idec).  JC polyomavirus (JCV) is the causative ... host-directed tyrosine kinase inhibitor in an extended release ...
(Date:5/23/2013)... , May 23, 2013 ... MKT: NSPR), the leader in embolic protection stents, ... (MGuard for Acute ST Elevation Reperfusion) trial demonstrating ... bare metal and drug eluting stents in all-cause ... patients.  Results from the trial were presented at ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: